Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Subasumstat - Takeda Oncology

Next Previous
Drug Profile

Subasumstat - Takeda Oncology

Alternative Names: TAK-981

Latest Information Update: 20 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda Oncology
  • Developer Presage Biosciences; Takeda Oncology
  • Class Amines; Antineoplastics; Chlorinated hydrocarbons; Cyclopentanes; Isoquinolines; Pyrimidines; Small molecules; Sulfonamides; Thiophenes
  • Mechanism of Action Small ubiquitin-related modifier protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
  • No development reported B-cell lymphoma; Chronic lymphocytic leukaemia; Head and neck cancer

Most Recent Events

  • 12 Feb 2024 Subasumstat is still in phase I/II trials for Solid tumours (Late-stage disease, Metastatic disease) and Lymphoma (Second-line therapy or greater) in USA (NCT03648372)
  • 12 Feb 2024 Takeda terminates a phase I/II trial in Solid tumours (Late-stage disease, Metastatic disease) and Lymphoma (Second-line therapy or greater) in USA due to enrolment challenges (NCT03648372)
  • 28 Jan 2024 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top